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Abstract: OBJECTIVES The aim of this study was to compare transcatheter aortic valve replacement
(TAVR) with the Acurate neo (NEO) and Evolut PRO (PRO) devices. BACKGROUND The NEO
and PRO bioprostheses are 2 next-generation self-expanding devices developed for TAVR. METHODS
The NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart
Valves) registry retrospectively included patients who underwent transfemoral TAVR with either NEO or
PRO valves at 24 centers between January 2012 and March 2018. One-to-one propensity score matching
resulted in 251 pairs. Pre-discharge and 30-day Valve Academic Research Consortium (VARC)-2 defined
outcomes were evaluated. Binary logistic regression was performed to adjust the treatment effect for
propensity score quintiles. RESULTS A total of 1,551 patients (n = 1,263 NEO; n = 288 PRO) were
included. The mean age was 82 years, and the mean Society of Thoracic Surgeons score was 5.1%. After
propensity score matching (n = 502), VARC-2 device success (90.6% vs. 91.6%; p = 0.751) and pre-
discharge moderate to severe (II+) paravalvular aortic regurgitation (7.3% vs. 5.7%; p = 0.584) were
comparable between the NEO and PRO groups. Furthermore, there were no significant differences in
any 30-day clinical outcome between matched NEO and PRO pairs, including all-cause mortality (3.2%
vs. 1.2%; p = 0.221), stroke (2.4% vs. 2.8%; p = 1.000), new permanent pacemaker implantation
(11.0% vs. 12.8%; p = 0.565), and VARC-2 early safety endpoint (10.6% vs. 10.4%; p = 1.000). Logistic
regression on the unmatched cohort confirmed a similar risk of VARC-2 device success, paravalvular aortic
regurgitation II+, and 30-day clinical outcomes after NEO and PRO implantation. CONCLUSIONS In
this multicenter registry, transfemoral TAVR with the NEO and PRO bioprostheses was associated with
high device success, acceptable rates of paravalvular aortic regurgitation II+, and good 30-day clinical
outcomes. After adjusting for potential confounders, short-term outcomes were similar between the
devices.
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ABSTRACT
OBJECTIVES The aim of this study was to compare transcatheter aortic valve replacement (TAVR) with the
Acurate neo (NEO) and Evolut PRO (PRO) devices.
BACKGROUND The NEO and PRO bioprostheses are 2 next-generation self-expanding devices developed for TAVR.
METHODS The NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves)
registry retrospectively included patients who underwent transfemoral TAVR with either NEO or PRO valves at 24 centers
between January 2012 and March 2018. One-to-one propensity score matching resulted in 251 pairs. Pre-discharge
and 30-day Valve Academic Research Consortium (VARC)–2 defined outcomes were evaluated. Binary logistic regression
was performed to adjust the treatment effect for propensity score quintiles.
RESULTS A total of 1,551 patients (n ¼ 1,263 NEO; n ¼ 288 PRO) were included. The mean age was 82 years, and the
mean Society of Thoracic Surgeons score was 5.1%. After propensity score matching (n ¼ 502), VARC-2 device success
(90.6% vs. 91.6%; p ¼ 0.751) and pre-discharge moderate to severe (IIþ) paravalvular aortic regurgitation (7.3% vs.
5.7%; p ¼ 0.584) were comparable between the NEO and PRO groups. Furthermore, there were no significant differences
in any 30-day clinical outcome between matched NEO and PRO pairs, including all-cause mortality (3.2% vs. 1.2%;
p ¼ 0.221), stroke (2.4% vs. 2.8%; p ¼ 1.000), new permanent pacemaker implantation (11.0% vs. 12.8%; p ¼ 0.565),
and VARC-2 early safety endpoint (10.6% vs. 10.4%; p ¼ 1.000). Logistic regression on the unmatched cohort confirmed
a similar risk of VARC-2 device success, paravalvular aortic regurgitation IIþ, and 30-day clinical outcomes after NEO and
PRO implantation.
CONCLUSIONS In this multicenter registry, transfemoral TAVR with the NEO and PRO bioprostheses was
associated with high device success, acceptable rates of paravalvular aortic regurgitation IIþ, and good 30-day clinical
outcomes. After adjusting for potential confounders, short-term outcomes were similar between the devices.
(J Am Coll Cardiol Intv 2019;12:433–43) © 2019 Published by Elsevier on behalf of the American College of Cardiology
Foundation.
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T
ranscatheter aortic valve replace-
ment (TAVR) has revolutionized the
treatment of patients with severe,
symptomatic aortic stenosis, becoming a
first-line therapeutic option among patients
at increased surgical risk (1,2). As a result
of continuous TAVR evolution, several
next-generation transcatheter heart valves
(THVs) have been developed to minimize
procedural complications and improve pa-
tients’ outcomes (3).
The Acurate neo (NEO) biopros-
thesis (developed by Symetis, Ecublens,
Switzerland; now Boston Scientific, Marl-
borough, Massachusetts) is a next-generation
self-expanding THV commercially available
for TAVR in several countries. Interesting
clinical and echocardiographic results have been
recently reported after transfemoral TAVR with the
NEO valve (4,5), and 2 randomized controlled trials are
currently ongoing to compare such device with the
SAPIEN 3 and the Evolut R THVs (SCOPE I [Safety and
Efficacy of the Symetis Acurate Neo/TF Compared to
the Edwards SAPIEN 3 Bioprosthesis; NCT03011346]
and SCOPE II [Safety and Efficacy Comparison Of Two
TAVI Systems in a Prospective Randomized Evaluation
II; NCT03192813], respectively). Recently, the self-
expanding Evolut PRO (PRO) system, the latest gen-
eration device in the CoreValve family (Medtronic,
Minneapolis, Minnesota), has shown excellent out-
comes in the prospective Medtronic Evolut PRO US
Clinical Study and has been introduced into clinical
practice (6).
To date, no study exists comparing the NEO
and latest generation PRO devices; furthermore, the
ongoing SCOPE II trial was designed to compare
SEE PAGE 444
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AND ACRONYMS
AV = aortic valve
CI = confidence interval
LVOT = left ventricular outflow
tract
NEO = Acurate neo
ORadj = adjusted odds ratio
PAR = paravalvular aortic
regurgitation
PPI = permanent pacemaker
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TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart valve
VARC-2 = Valve Academic
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the NEO valve with the second-generation Evolut R
device. Therefore, our aim was to perform a multi-
center observational study to compare clinical and
echocardiographic outcomes after transfemoral TAVR
with the next-generation self-expanding NEO and
PRO THVs.
METHODS
STUDY POPULATION. Our multicenter, observa-
tional, retrospective NEOPRO (A Multicenter Com-
parison of Acurate NEO Versus Evolut PRO
Transcatheter Heart Valves) registry included a total
of 1,551 patients who underwent transfemoral TAVR
with either NEO (n ¼ 1,263) or PRO (n ¼ 288) devices
between January 2012 and March 2018 at 24 centers.
The number of patients included from each partici-
pating center is detailed in Online Table 1. All
consecutive patients treated with transfemoral TAVR
for symptomatic, severe aortic stenosis of the native
aortic valve (AV) with either NEO or PRO implantation
were included in the registry. The treatment period
was January 2012 to March 2018 for the NEO device
and August 2017 to March 2018 for the PRO device.
Local multidisciplinary heart teams evaluated all
cases and confirmed eligibility for transfemoral
TAVR. All patients provided written informed con-
sent for the procedure and subsequent data collection
per local practice for retrospective data.
Pre-procedural screening was performed by means
of clinical assessment (patient demographics, symp-
toms, comorbidities, laboratory examinations, and
risk evaluation), echocardiography, and multidetector
computed tomography. Native AV and left ventricular
outflow tract (LVOT) calcifications were classified and
graded using a semiquantitative scoring system, as
previously described (7). The selection of prosthesis
type and size was at the discretion of the treating
physician at each center.
DEVICE DESCRIPTION. The NEO bioprosthesis is
implanted using a dedicated transfemoral delivery
system inserted through a 20-F sheath, as previously
described (8). The device is available in sizes small,
medium, and large, which correspond to annular
diameters of 23, 25, and 27 mm, respectively. The self-
expanding nitinol frame has porcine pericardial valve
leaflets in a supra-annular position, with a pericardial
sealing skirt on the outer and inner surface of the
stent body.
The PRO bioprosthesis is delivered transfemorally
using a dedicated sheathless delivery system with an
outer diameter similar to a 16-F sheath. The device
has similar properties to the second-generation Evo-
lut R THV (9); the principal design modification is the
presence of an external pericardial wrap to enhance
annular sealing. The PRO valve is currently available
in 23-, 26-, and 29-mm sizes.
STUDY ENDPOINTS. The primary endpoint of the
study was post-procedural device success, defined
according to Valve Academic Research Consortium–2
(VARC-2) criteria (10). Secondary endpoints of inter-
est were procedural complications and VARC-2-
defined clinical outcomes at 30 days (including the
early safety composite endpoint). Echocardiographic
outcomes were evaluated pre-discharge; paravalvular
aortic regurgitation (PAR) severity was assessed
according to VARC-2 criteria and classified as follows:
none or trace, mild, moderate, and severe (10).
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD and were compared using
the unpaired Student’s t-test. Categorical variables
are presented as numbers and percentages and were
compared using the Fisher exact test (given the high
frequency of low proportions).
Propensity score (PS) matching was used to adjust
for differences in baseline characteristics and poten-
tial confounders that may lead to biased estimates
of treatment outcomes (11,12). A PS was calculated
for each patient to estimate the propensity toward
belonging to a specific treatment group (NEO vs. PRO).
This was done by means of a nonparsimonious multi-
variate logistic regression including the following
covariates: age, sex, body mass index, diabetes
mellitus, chronic obstructive pulmonary disease,
estimated glomerular filtration rate, prior myocardial
infarction, peripheral vascular disease, prior cardiac
surgery, prior balloon aortic valvuloplasty, previous
pacemaker or implantable cardioverter-defibrillator,
New York Heart Association functional class III or IV,
left ventricular ejection fraction, Society of Thoracic
Surgeons Predicted Risk of Mortality score, moderate
to heavy AV calcification, and moderate to severe
LVOT calcification. The C statistic for the PSmodel was
0.78, indicating good discrimination. The Hosmer-
Lemeshow goodness-of-fit test p value was 0.35, con-
firming good calibration and fit of the multivariate
model. A 1-to-1 nearest neighbor matching algorithm
without replacement (caliper 0.20) was performed
to identify PS-matched pairs. The pseudo-R2 value
was 0.08 (p < 0.0001) before matching and very low
(0.007; p ¼ 0.995) after matching, thus confirming
the good quality of the match and the adequate
balancing of covariate distribution between the
matched groups (13).
Pre-specified primary and secondary endpoints
were compared between the NEO and PRO groups
in both the overall and PS-matched cohorts. In the
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overall cohort, binary logistic regression was also
performed to adjust the treatment effect for the PS
quintiles. Results of the binary logistic regression are
presented as adjusted odds ratio (ORadj) with 95%
confidence interval (CI). The primary endpoint was
evaluated in clinically relevant subgroups of the
entire population with a post hoc formal interaction
testing analysis.
All reported p values are 2 sided, and a p value
<0.05 was considered to indicate statistical signifi-
cance. All statistical analyses were performed using
Stata version 13.0 (STATACorp, College Station, Texas).
RESULTS
BASELINE PATIENT CHARACTERISTICS. A total of
1,551 patients who underwent transfemoral TAVR
with the NEO (n ¼ 1,263) or PRO (n ¼ 288) THV were
included. Baseline characteristics of the entire study
population are shown in Table 1. The mean age was
81.8  5.8 years, and 35.3% of patients were men; the
mean Society of Thoracic Surgeons Predicted Risk of
Mortality score was 5.1  3.4%. Patients treated
with the NEO were more frequently in New York
Heart Association functional class III or IV (77.8%
vs. 66.9%; p < 0.001). Patients treated with the PRO
more frequently had peripheral vascular disease
(24.3% vs. 12.4%; p < 0.001), history of myocardial
infarction (22.7% vs. 11.5%; p < 0.001), and history of
previous balloon aortic valvuloplasty (5.3% vs. 2.4%;
p ¼ 0.017). Severity of AV calcification was higher in
the PRO group, while degrees of LVOT calcification were
similar among the NEO and PRO groups (Table 1).
A 1-to-1 PS matching analysis (for variables sum-
marized in “Methods”) resulted in a total of 251
matched pairs. As shown in Table 1, there was no
significant difference in any baseline characteristic
among the PS-matched NEO and PRO groups,
including the degrees of AV and LVOT calcification.
PROCEDURAL CHARACTERISTICS. Procedural char-
acteristics of the entire population are depicted in
Table 2. Most patients underwent TAVR under
conscious sedation (87.7%), with a significantly
higher rate in the PRO group (92.3% vs. 86.7%;
p ¼ 0.007). Pre-dilatation and post-dilatation were
more frequent in the NEO group (pre-dilatation,
83.3% vs. 37.1%; post-dilatation, 41.7% vs. 23.7%;
p < 0.001 for both). The type of vascular closure
technique was different between groups, with
ProGlide and Manta used more frequently in the
PRO group and Prostar used more frequently in
the NEO group (p < 0.001). VARC-2 periprocedural
complications were similar between the groups,
except for pericardial tamponade that was higher
in the NEO group (1.6% vs. 0.0%; p ¼ 0.036).
Overall, 4 patients had coronary obstruction: 2
patients had coronary obstruction after THV emboli-
zation and subsequent valve-in-valve implantation
(1 in the NEO group and 1 in the PRO group); 1 patient
had annular rupture after NEO implantation as a
result of post-dilatation, eventually leading to
an aorto–right ventricular fistula and right coronary
artery obstruction; and 1 patient had cardiac arrest
1 day after NEO implantation with evidence on
coronary angiography of left circumflex artery
thrombosis.
After PS matching, conscious sedation was similar
between the NEO and PRO groups (96.4% vs. 92.8%;
p ¼ 0.112), while the use of pre-dilatation and
post-dilatation remained significantly higher in
the NEO group (pre-dilatation, 86.5% vs. 37.9%; post-
dilatation, 41.4% vs. 25.0%; p < 0.001 for both). There
was no significant difference in any peri-procedural
complication after PS matching, including pericar-
dial tamponade, second THV implantation, valve
embolization, annular rupture, aortic dissection,
coronary occlusion, and conversion to open surgery
(Table 2). Length of hospital stay was similar between
matched NEO and PRO groups (p ¼ 0.129).
EARLY ECHOCARDIOGRAPHIC OUTCOMES. Early
echocardiographic data after TAVR (before discharge)
are shown in Table 2. The mean AV gradient was
significantly higher after NEO implantation (8.5 
4.0 mm Hg vs. 7.2  3.5 mm Hg; p < 0.001), although
the proportion of patients with mean AV gradients
$20 mm Hg was similar between groups (1.2% vs.
1.1%; p ¼ 1.000). As depicted in Figure 1, the overall
amount of PAR was higher after NEO implantation
(p < 0.001), driven by a higher rate of none or trace
PAR in the PRO group (52.1% vs. 37.9%). The inci-
dence of moderate-to-severe PAR was similar be-
tween the PRO and NEO groups (5.7% vs. 5.2%;
p ¼ 0.659). After adjustment for PS quintiles, the risk
for moderate-to-severe PAR remained similar with
the PRO and NEO devices (ORadj: 0.85; 95% CI: 0.46 to
1.60; p ¼ 0.625).
In the PS-matched population (Table 2), the mean
AV gradient remained higher after NEO implantation
(8.3  4.0 mm Hg vs. 7.3  3.6 mm Hg; p ¼ 0.003),
with no significant difference in mean AV gradient
$20 mm Hg between matched NEO and PRO pairs
(1.2% vs. 1.3%; p ¼ 1.000). The overall amount of
PAR was not different between the matched groups
(p ¼ 0.055) (Figure 1), with a similar rate of moderate-
to-severe PAR after NEO and PRO implantation (7.3%
vs. 5.7%; p ¼ 0.584).
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TABLE 1 Baseline Patients Characteristics Before and After Propensity Score Matching












(n ¼ 251) p Value
Clinical characteristics













Male 548/1,551 (35.3) 444/1,263 (35.2) 104/288 (36.1) 0.785 172/502 (34.3) 86/251 (34.3) 86/251 (34.3) 1.000













COPD 294/1,548 (19.0) 244/1,262 (19.3) 50/286 (17.5) 0.505 92/502 (18.3) 46/251 (18.3) 46/251 (18.3) 1.000
Diabetes mellitus 455/1,546 (29.4) 379/1,262 (30.0) 76/284 (26.8) 0.281 140/502 (27.9) 72/251 (28.7) 68/251 (27.1) 0.765
Hypertension 1,312/1,489 (88.1) 1,079/1,226 (88.0) 233/263 (88.6) 0.834 428/424 (88.4) 224/251 (89.2) 204/233 (87.6) 0.573


























eGFR <30 ml/min/1.73 m2 141/1,546 (9.1) 113/1,258 (9.0) 28/288 (9.7) 0.733 46/502 (9.2) 23/251 (9.2) 23/251 (9.2) 1.000
Dialysis 30/1,548 (1.9) 22/1,262 (1.7) 8/286 (2.8) 0.238 11/502 (2.2) 4/251 (1.6) 7/251 (2.8) 0.544




178/1,549 (11.5) 154/1,263 (12.2) 24/286 (8.4) 0.080 41/502 (8.2) 21/251 (8.4) 20/251 (8.0) 1.000
Prior CABG 169/1,549 (10.9) 147/1,263 (11.6) 22/286 (7.7) 0.058 39/502 (7.8) 20/251 (8.0) 19/251 (7.6) 0.868
Prior MV surgery 9/1,549 (0.6) 7/1,263 (0.6) 2/286 (0.7) 0.675 2/502 (0.4) 1/251 (0.4) 1/251 (0.4) 1.000
Prior BAV 41/1,387 (3.0) 26/1,102 (2.4) 15/285 (5.3) 0.017 17/502 (3.4) 6/251 (2.4) 11/251 (4.4) 0.324
Peripheral vascular disease 225/1,546 (14.6) 156/1,262 (12.4) 69/284 (24.3) <0.001 124/502 (24.7) 62/251 (24.7) 62/251 (24.7) 1.000
Prior stroke 148/1,512 (9.8) 126/1,226 (10.3) 22/286 (7.7) 0.224 44/502 (8.8) 25/251 (10.0) 19/251 (7.6) 0.430
Atrial fibrillation/flutter 506/1,539 (32.9) 408/1,253 (32.6) 98/286 (34.3) 0.578 184/502 (36.7) 93/251 (37.1) 91/251 (36.3) 0.926
PM or ICD 184/1,550 (11.9) 158/1,262 (12.5) 26/288 (9.0) 0.106 44/502 (8.8) 21/251 (8.4) 23/251 (9.2) 0.875
NYHA functional class III or IV 1,173/1,548 (75.8) 981/1,261 (77.8) 192/287 (66.9) <0.001 344/502 (68.5) 175/251 (69.7) 169/251 (67.3) 0.631




































































Moderate to severe AR 213/1,507 (14.1) 177/1,227 (14.4) 36/280 (12.9) 0.568 71/495 (14.3) 41/249 (16.5) 30/246 (12.2) 0.200















214/1,261 (17.0) 169/976 (17.3) 45/285 (15.8) 0.591 77/463 (16.6) 36/214 (16.8) 41/249 (16.5) 1.000
Moderate to severe MR 357/1,504 (23.7) 282/1,226 (23.0) 75/278 (27.0) 0.161 132/492 (26.8) 72/247 (29.2) 60/245 (24.5) 0.264
Moderate to severe TR 263/1,489 (17.7) 209/1,215 (17.2) 54/274 (19.7) 0.335 93/489 (19.0) 45/247 (18.2) 48/242 (19.8) 0.730
MDCT
AV calcification <0.001 0.313
None 5/1,243 (0.4) 4/977 (0.4) 1/266 (0.4) 2/502 (0.4) 1/251 (0.4) 1/251 (0.4)
Mild 323/1,243 (26.0) 282/977 (28.9) 41/266 (15.4) 76/502 (15.1) 37/251 (14.7) 39/251 (15.5)
Moderate 545/1,243 (43.9) 428/977 (43.8) 117/266 (44.0) 241/502 (48.0) 130/251 (51.8) 111/251 (44.2)
Heavy 370/1,243 (29.8) 263/977 (26.9) 107/266 (40.2) 183/502 (36.5) 83/251 (33.1) 100/251 (39.8)
LVOT calcification 0.229 0.206
None 682/1,246 (54.7) 541/975 (55.5) 141/271 (52.0) 243/502 (48.4) 113/251 (45.0) 130/251 (51.8)
Mild 337/1,246 (27.0) 265/975 (27.2) 72/271 (26.6) 139/502 (27.7) 72/251 (28.7) 67/251 (26.7)
Moderate 138/1,246 (11.1) 107/975 (11.0) 31/271 (11.4) 75/502 (14.9) 45/251 (17.9) 30/251 (12.0)
Severe 89/1,246 (7.1) 62/975 (6.4) 27/271 (10.0) 45/502 (9.0) 21/251 (8.4) 24/251 (9.6)
Values are mean  SD or n/N (%). *Systolic pulmonary artery pressure on echocardiography >55 mm Hg.
AR ¼ aortic regurgitation; AV ¼ aortic valve; AVA ¼ aortic valve area; BAV ¼ balloon aortic valvuloplasty; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive
pulmonary disease; eGFR ¼ estimated glomerular filtration rate; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; ICD ¼ implantable cardioverter-defibrillator; LVEF ¼ left ventricular
ejection fraction; LVOT ¼ left ventricular outflow tract; MDCT ¼ multidetector computed tomography; MI ¼ myocardial infarction; MR ¼ mitral regurgitation; MV ¼ mitral valve; NYHA ¼ New York Heart
Association; PCI ¼ percutaneous coronary intervention; PM ¼ pacemaker; PS ¼ propensity score; STS-M ¼ Society of Thoracic Surgeons Predicted Risk of Mortality; TR ¼ tricuspid regurgitation.
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VARC-2 DEVICE SUCCESS AND 30-DAY CLINICAL
OUTCOMES. Device success was 91.7%, with a similar
rate between the NEO and PRO groups (92.0% vs.
90.7%; p ¼ 0.539). Information on 30-day survival
status was available for 1,544 of 1,551 patients
(99.5%), with 43 deaths in the 30-day period after
TAVR (all-cause mortality rate 2.8%); the remaining 7
patients were lost to follow-up. As shown in Table 3,
in the entire population there were no significant
differences in all-cause mortality (3.0% vs. 1.8%;
p ¼ 0.319) and cardiovascular mortality (2.3% vs. 1.1%;
p ¼ 0.249) at 30 days. Rates of hospitalization for
valve-related symptoms or worsening congestive
heart failure, any stroke, disabling stroke, myocardial
infarction, acute kidney injury stage 2 or 3, coronary
obstruction, valve embolization or migration, endo-
carditis, THV thrombosis, and valve dysfunction
requiring repeat procedure did not differ between the
NEO and PRO groups (Table 3). TAVR with NEO was
associated with a higher rate of any bleeding (14.9%
vs. 8.5%; p ¼ 0.004) and any vascular complication
(8.1% vs. 4.6%; p ¼ 0.025), with no significant dif-
ferences in life-threatening bleeding, major bleeding,
and major vascular complications between the NEO
and PRO groups. The unadjusted rate of new perma-
nent pacemaker implantation (PPI) was higher with
TABLE 2 Procedural Characteristics and Early Echocardiographic Outcomes Before and After Propensity Score Matching












(n ¼ 251) p Value
Procedural characteristics
Conscious sedation 1,359/1,549 (87.7) 1,094/1,262 (86.7) 265/287 (92.3) 0.007 475/502 (94.6) 242/251 (96.4) 233/251 (92.8) 0.112
Valve size
Small — 348/1,262 (27.6) — — 60/251 (23.9) —
Medium — 520/1,262 (41.2) — — 105/251 (41.8) —
Large — 394/1,262 (31.2) — — 86/251 (34.3) —
23 mm — — 7/288 (2.4) — — 5/251 (2.0)
26 mm — — 108/288 (37.5) — — 96/251 (38.3)
29 mm — — 173/288 (60.1) — — 150/251 (59.8)
Pre-dilatation 1,156/1,545 (74.8) 1,051/1,262 (83.3) 105/283 (37.1) <0.001 311/499 (62.3) 217/251 (86.5) 94/248 (37.9) <0.001
Post-dilatation 593/1,544 (38.4) 526/1,261 (41.7) 67/283 (23.7) <0.001 166/499 (33.3) 104/251 (41.4) 62/248 (25.0) <0.001
Vascular closure technique <0.001 <0.001
ProGlide 946/1,550 (61.0) 717/1,262 (56.8) 229/288 (79.5) 344/502 (68.5) 138/251 (54.5) 206/251 (82.1)
Prostar 555/1,550 (35.8) 525/1,262 (41.6) 30/288 (10.4) 129/502 (25.7) 108/251 (43.0) 21/251 (8.4)
Manta 47/1,550 (3.0) 19/1,262 (1.5) 28/288 (9.7) 28/502 (5.6) 5/251 (2.0) 23/251 (9.2)
Surgical closure 2/1,550 (0.1) 1/1,262 (0.1) 1/288 (0.4) 1/502 (0.2) 0/251 (0.0) 1/251 (0.4)
Valve repositioning — — 21/264 (8.0) — — — 20/233 (8.6) —
Second THV implanted 20/1,551 (1.3) 14/1,263 (1.1) 6/288 (2.1) 0.240 5/502 (1.0) 2/251 (0.8) 3/251 (1.2) 1.000
Valve embolization 16/1,551 (1.0) 13/1,263 (1.0) 3/288 (1.0) 1.000 3/502 (0.6) 1/251 (0.4) 2/251 (0.8) 1.000
Annular rupture 4/1,551 (0.3) 4/1,263 (0.3) 0/288 (0.0) 1.000 0/502 (0.0) 0/251 (0.0) 0/251 (0.0) —
Pericardial tamponade 20/1,551 (1.3) 20/1,263 (1.6) 0/288 (0.0) 0.036 5/502 (1.0) 5/251 (2.0) 0/251 (0.0) 0.061
Aortic dissection 1/1,551 (0.1) 1/1,263 (0.1) 0/288 (0.0) 1.000 0/502 (0.0) 0/251 (0.0) 0/251 (0.0) —
Coronary occlusion 3/1,551 (0.2) 2/1,263 (0.2) 1/288 (0.4) 0.460 0/502 (0.0) 0/251 (0.0) 0/251 (0.0) —
Conversion to surgery 13/1,551 (0.8) 13/1,263 (1.0) 0/288 (0.0) 0.144 2/502 (0.4) 2/251 (0.8) 0/251 (0.0) 0.499




























Mean AV gradient $20 mm Hg 17/1,416 (1.2) 14/1,145 (1.2) 3/271 (1.1) 1.000 6/483 (1.2) 3/245 (1.2) 3/238 (1.3) 1.000
Moderate to severe total AR 84/1,481 (5.7) 68/1,201 (5.7) 16/280 (5.7) 1.000 32/492 (6.5) 18/247 (7.3) 14/245 (5.7) 0.584
Moderate tosevereparavalvularAR 78/1,481 (5.3) 62/1,201 (5.2) 16/280 (5.7) 0.659 32/492 (6.5) 18/247 (7.3) 14/245 (5.7) 0.584













VARC-2 device success 1,297/1,414 (91.7) 1,052/1,144 (92.0) 245/270 (90.7) 0.539 439/482 (91.1) 222/245 (90.6) 217/237 (91.6) 0.751
Values are n/N (%) or mean  SD.
THV ¼ transcatheter heart valve; VARC-2 ¼ Valve Academic Research Consortium–2; other abbreviations as in Table 1.
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the PRO compared with the NEO (13.2% vs. 8.8%;
p ¼ 0.045). The VARC-2 safety composite endpoint
at 30 days (all-cause mortality, any stroke, life-
threatening bleeding, acute kidney injury stage 2
or 3, coronary obstruction, major vascular complica-
tions, or valve dysfunction requiring repeat proced-
ure) was higher in the NEO group (16.4% vs. 10.9%;
p ¼ 0.025).
After adjustment for PS quintiles, VARC-2 device
success was similar with the PRO and NEO devices
(ORadj: 1.15; 95% CI: 0.68 to 1.96; p ¼ 0.598). Similarly,
the implanted valve did not have a significant impact
on all-cause mortality (ORadj: 0.42; 95% CI: 0.12 to
1.43; p ¼ 0.166), cardiovascular mortality (ORadj: 0.19;
95% CI: 0.02 to 1.42; p ¼ 0.104), hospitalization for
valve-related symptoms or worsening congestive
heart failure (ORadj: 2.21; 95% CI: 0.80 to 6.11;
p ¼ 0.126), any stroke (ORadj: 1.15; 95% CI: 0.47 to
2.82; p ¼ 0.758), any bleeding (ORadj: 0.63; 95% CI:
0.38 to 1.03; p ¼ 0.067), any vascular complication
(ORadj: 0.75; 95% CI: 0.48 to 1.16; p ¼ 0.196), new PPI
(ORadj: 1.49; 95% CI: 0.93 to 2.39; p ¼ 0.100), and
VARC-2 early safety composite endpoint (ORadj: 0.76;
95% CI: 0.48 to 1.20; p ¼ 0.234) at 30 days.
No significant interactions between implanted
valve and relevant subgroups with respect to VARC-2
device success were observed in the overall popula-
tion (Online Figure 1).
In the PS-matched population, VARC-2 device
success was similar between the NEO and PRO groups
(90.6% vs. 91.6%; p ¼ 0.751). There were no
significant differences in any other 30-day clinical
outcome between matched NEO and PRO pairs
(Table 3), including all-cause mortality (3.2% vs. 1.2%;
p ¼ 0.221), cardiovascular mortality (2.4% vs. 0.4%;
p ¼ 0.122), any stroke (2.4% vs. 2.8%; p ¼ 1.000), any
bleeding (13.0% vs. 8.4%; p ¼ 0.112), any vascular
complication (14.2% vs. 11.7%; p ¼ 0.424), new PPI
(11.0% vs. 12.8%; p ¼ 0.565), and VARC-2 early safety
composite endpoint (10.6% vs. 10.4%; p ¼ 1.000).
DISCUSSION
Our multicenter study represents the first comparison
of transfemoral TAVR with the next-generation self-
expanding NEO and PRO devices in a total of 1,551
patients. The main findings of our registry are as
follows. 1) VARC-2 device success was obtained in
91.7% of patients, with similar rates after NEO and
PRO implantation in the entire population, after
adjustment for PS quintiles, and in the PS-matched
cohort. 2) The rate of moderate to severe PAR after
TAVR was acceptable (5.3%), with no difference
between the NEO and PRO groups in the entire pop-
ulation, after adjustment for PS quintiles, and in
the PS-matched cohort. 3) In the overall population,
the rate of new PPI was higher after PRO implantation
(13.2% vs. 8.8%), and the VARC-2 early safety com-
posite endpoint was higher after NEO implantation
(16.4% vs. 10.9%); however, there was no difference
in any 30-day clinical endpoint after adjustment for
PS quintiles and in the PS-matched groups.
FIGURE 1 Paravalvular Aortic Regurgitation After Transcatheter Aortic Valve Replacement
Grades of paravalvular aortic regurgitation after transcatheter aortic valve replacement (TAVR) are presented for both the entire population
(A) and the propensity score (PS)–matched cohort (B).
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VARC-2 DEVICE SUCCESS. A high rate of VARC-2
device success (91.7%) was obtained in our real-
world TAVR population treated with the latest
generation NEO and PRO THVs, with a similar rate
between both treatment groups (NEO 92.0%, PRO
90.7%). This finding was confirmed also after adjust-
ment for PS quintiles and in the PS-matched groups
(251 pairs). Furthermore, the rates of moderate-to-
severe PAR and elevated gradients (mean AV
gradient $20 mm Hg) were comparable between the
NEO and PRO groups.
Recently, the prospective Evolut PRO US Clinical
Study reported a high rate of device success with the
PRO device (84.0%) (6). Regarding the NEO valve, a
very high device success rate (98.7%) was reported in
the largest available prospective registry (5), whereas
2 recent studies reported similar rates (89.0% and
89.6%) compared with our NEOPRO registry (14,15).
Pending the results of the SCOPE II trial, there is a
lack of randomized data comparing the safety and
performance of self-expanding THVs. In this context,
our study reports a similar rate of VARC-2 device
success between the next-generation NEO and PRO
valves, also after adjustment for a range of baseline
clinical and anatomic variables that may affect pro-
cedural outcome.
PARAVALVULAR LEAK. In our study, the incidence
of moderate-to-severe PAR prior to discharge was
5.3%, with a similar rate after NEO and PRO implan-
tation (5.2% vs. 5.7%); this finding was confirmed
also after adjustment for PS quintiles and in the
PS-matched cohort. The PRO device was specifically
designed to enhance annular sealing compared with
the earlier generation Evolut R (by means of an
external pericardial wrap), thus aiming to reduce
PAR. As a result of progressive device evolution, the
rate of moderate-to-severe PAR after TAVR has
been progressively reduced with iterations of Cor-
eValve THVs: 8% to 10% with the first-generation
CoreValve (10.5% in the CoreValve US Pivotal
Extreme Risk Trial [16], 7.8% in the CoreValve US
TABLE 3 Clinical Outcomes at 30 Days Before and After Propensity Score Matching












(n ¼ 251) p Value
All-cause mortality 43/1,544 (2.8) 38/1,258 (3.0) 5/286 (1.8) 0.319 11/501 (2.2) 8/251 (3.2) 3/250 (1.2) 0.221
Cardiovascular mortality 32/1,544 (2.1) 29/1,258 (2.3) 3/286 (1.1) 0.249 7/501 (1.4) 6/251 (2.4) 1/250 (0.4) 0.122
Hospitalization for valve-related
symptoms or worsening CHF
19/1,300 (1.5) 12/1,016 (1.2) 7/284 (2.5) 0.156 10/494 (2.0) 3/245 (1.2) 7/249 (2.8) 0.339
Any stroke 39/1,529 (2.1) 25/1,245 (2.0) 7/284 (2.5) 0.645 13/496 (2.6) 6/247 (2.4) 7/249 (2.8) 1.000
Disabling stroke 24/1,529 (1.6) 20/1,245 (1.6) 4/284 (1.4) 1.000 9/496 (1.8) 5/247 (2.0) 4/249 (1.6) 0.751
MI 8/1,476 (0.5) 7/1,192 (0.6) 1/284 (0.4) 1.000 2/499 (0.4) 1/250 (0.4) 1/249 (0.4) 1.000
Any bleeding 201/1,472 (13.7) 177/1,188 (14.9) 24/284 (8.5) 0.004 53/496 (10.7) 32/247 (13.0) 21/249 (8.4) 0.112
Life-threatening 28/1,472 (1.9) 25/1,188 (2.1) 3/284 (1.1) 0.335 8/496 (1.6) 6/247 (2.4) 2/249 (0.8) 0.175
Major 64/1,472 (4.4) 56/1,188 (4.7) 8/284 (2.8) 0.195 16/496 (3.2) 10/247 (4.1) 6/249 (2.4) 0.323
Minor 109/1,472 (7.4) 96/1,188 (8.1) 13/284 (4.6) 0.044 29/496 (5.9) 16/247 (6.5) 13/249 (5.2) 0.572
Any vascular complication 246/1,529 (16.1) 213/1,245 (17.1) 33/284 (11.6) 0.025 64/496 (12.9) 35/247 (14.2) 29/249 (11.7) 0.424
Major 85/1,529 (5.6) 75/1,245 (6.0) 10/284 (3.5) 0.114 20/496 (4.0) 12/247 (4.9) 8/249 (3.2) 0.372
Minor 161/1,529 (10.5) 138/1,245 (11.1) 23/284 (8.1) 0.163 44/496 (8.9) 23/247 (9.3) 21/249 (8.4) 0.754
AKI stage 2 or 3 43/1,469 (2.9) 37/1,185 (3.1) 6/284 (2.1) 0.438 10/495 (2.0) 6/246 (2.4) 4/249 (1.6) 0.543
Coronary obstruction 4/1,530 (0.3) 3/1,245 (0.2) 1/285 (0.4) 0.562 0/496 (0.0) 0/247 (0.0) 0/249 (0.0) -
Valve embolization or migration 17/1,532 (1.1) 14/1,247 (1.1) 3/285 (1.1) 1.000 3/497 (0.6) 1/247 (0.4) 2/250 (0.8) 1.000
Endocarditis 1/1,370 (0.1) 1/1,086 (0.1) 0/284 (0.0) 1.000 0/496 (0.0) 0/247 (0.0) 0/249 (0.0) -
THV thrombosis 0/1,300 (0.0) 0/1,016 (0.0) 0/284 (0.0) - 0/480 (0.0) 0/231 (0.0) 0/249 (0.0) -
Valve dysfunction requiring repeat
procedure (BAV, TAVR, or SAVR)
5/1,370 (0.4) 3/1,086 (0.3) 2/284 (0.7) 0.278 2/496 (0.4) 0/247 (0.0) 2/249 (0.8) 0.499
New permanent pacemaker
implantation*
130/1,347 (9.7) 96/1,089 (8.8) 34/258 (13.2) 0.045 54/453 (11.9) 25/227 (11.0) 29/226 (12.8) 0.565
VARC-2 early safety composite
endpoint
204/1,342 (15.2) 173/1,058 (16.4) 31/284 (10.9) 0.025 52/495 (10.5) 26/246 (10.6) 26/249 (10.4) 1.000
Values are n/N (%). *Excluding patients with pacemaker at baseline.
AKI ¼ acute kidney injury; BAV ¼ balloon aortic valvuloplasty; CHF ¼ congestive heart failure; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter aortic valve replacement; TIA ¼ transient
ischemic attack; other abbreviations as in Tables 1 and 2.
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Pivotal High Risk Trial [17], and 8.6% in the CHOICE
[Comparison of Transcatheter Heart Valves in High
Risk Patients With Severe Aortic Stenosis] trial [18]),
2% to 3% with the second-generation Evolut R (3.1%
in the CoreValve Evolut R US Study [19], 2.0% in the
CoreValve Evolut R FORWARD Study [20]), and 0%
with the latest generation PRO in the recent
Evolut PRO US Clinical Study (6). In our registry, we
observed a higher rate of moderate-to-severe PAR
after PRO implantation (5.7%) compared with the
Evolut PRO US Clinical Study (0%) (6). This finding
may be partially explained by the high percentage of
patients with moderate to heavy AV calcification
(84.2%) and any LVOT calcification (48.0%) treated
with PRO THV in our registry. This may reflect a se-
lection bias on the part of the operators who choose
the PRO in more challenging anatomies. The degrees
of AV and LVOT calcification were not reported in the
Evolut PRO US Clinical Study, thus preventing a
comparison of anatomic characteristics between the
2 patient populations. The NEO device features a
pericardial sealing skirt to minimize PAR and was
associated with a moderate-to-severe PAR rate of 4%
to 5% in previous studies (4,5,14). In our study, the
incidence of significant PAR after NEO implantation
was similar to that in previous NEO studies (5.2%),
with no differences compared with the latest gener-
ation PRO valve. Not surprisingly, we observed a
higher rate of both pre-dilatation and post-dilatation
in the NEO group, which may be related to the
lower radial force of this prosthesis and could have
had an impact on mitigating pre-discharge PAR rate.
Although there was no difference in significant PAR
at discharge, the lower rates of PAR may have been
obtained at the price of a higher need for pre-
dilatation and post-dilatation with NEO implanta-
tion, procedural steps that could potentially be linked
to a higher risk for adverse events such as annular
rupture, conduction disturbances requiring PPI (15),
or cerebrovascular events (21,22).
Despite a similar rate of moderate-to-severe PAR
between the NEO and PRO groups, the overall amount
of PAR was higher after NEO implantation in the
entire population, driven by a higher rate of mild PAR
in this group (56.9% vs. 42.1%). Because residual mild
PAR has been associated with worse prognosis (23,24)
and TAVR is expanding toward lower risk, younger,
and asymptomatic patients with expected longer
survival (3), we hope that future studies will further
evaluate the impact of mild PAR after TAVR.
NEW PERMANENT PACEMAKER. New conduction
disturbances requiring PPI still represent a major
concern of TAVR procedures, with highly variable
rates reported for both early- and next-generation
devices (25). In our registry, the incidence of new
PPI at 30 days was significantly higher after PRO
implantation in the entire population (13.2% vs.
8.8%), but this difference was not maintained after
adjustment for PS quintiles (ORadj: 1.49; 95% CI: 0.93
to 2.39; p ¼ 0.100) and in the PS-matched cohort
(12.8% vs. 11.0%). The rate of new PPI after NEO im-
plantation observed in our study (8.8% in the overall
cohort, 11.0% in the PS-matched cohort) is consistent
with rates reported in previous studies evaluating
this device (8% to 12%) (4,5,14,15,26). Regarding
CoreValve THVs, a progressive reduction in the
incidence of 30-day new PPI has been observed
with device iterations: 20% to 38% with the first-
generation CoreValve (21.6% in the CoreValve
US Pivotal Extreme Risk Trial [16], 19.8% in the
CoreValve US Pivotal High Risk Trial [17], 37.6% in the
CHOICE Trial [18]), 16% to 20% with the second-
generation Evolut R (16.4% in the CoreValve Evolut
R US Study [19], 19.7% in the CoreValve Evolut R
FORWARD Study [20]), and 11.8% with the latest
generation PRO in the Evolut PRO US Clinical Study
(6). This improvement may be determined by several
reasons, including device evolution, technical
refinement, careful patient selection, and increased
operator experience with new Evolut THV delivery
features (such as resheathing and recapturing). The
rate of new PPI after PRO observed in our registry
(13.2% in the overall cohort, 12.8% in the PS-matched
cohort) is consistent with that reported in the Evolut
PRO US Clinical Study (11.8%) (6). Our findings
confirm an acceptable incidence of new PPI with both
next-generation self-expanding devices, with no
significant differences between the NEO and PRO
THVs after adjustment for potential clinical and
anatomic confounders.
VARC-2 EARLY SAFETY COMPOSITE ENDPOINT AND
CLINICAL OUTCOMES AT 30 DAYS. The patient
population of the NEOPRO registry represents a real-
world TAVR population with mean age of 82 years
and increased surgical risk, thus reflecting current
clinical practice. The VARC-2 early safety composite
endpoint occurred in 15.2% of patients in the entire
population, significantly more common after NEO
implantation (16.4% vs. 10.9%), but this difference
was not maintained after adjustment for PS quintiles
(ORadj: 0.76; 95% CI: 0.48 to 1.20; p ¼ 0.234) and in
the PS-matched cohort (10.6% vs. 10.4%). Overall
rates of all-cause mortality (2.8%), cardiovascular
mortality (2.1%), any stroke (2.1%), and disabling
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stroke (1.6%) at 30 days were very low in our study,
consistent with previous studies evaluating NEO
and PRO devices (4–6,14). Importantly, there were
no significant differences in these major clinical out-
comes between the 2 treatment groups. Four cases of
coronary obstruction were observed in our registry,
which seemed to be related to periprocedural com-
plications (annular rupture, valve embolization, and
emergent valve-in-valve implantation) or unex-
plained coronary thrombosis and not to specific
device-related features. In the entire population,
rates of any vascular complication and any bleeding
were significantly higher after NEO implantation,
with no significant difference in major vascular
complications, life-threatening bleeding, and major
bleeding between the groups. Although these differ-
ences may be related to the use of different vascular
closure techniques between groups or to the lower
profile of the transfemoral delivery system of the PRO
THV (16-F sheath) compared with the NEO device
(20-F sheath), it is worth mentioning that such dif-
ferences were not maintained after adjustment for PS
quintiles and in the PS-matched cohort. Overall, good
clinical outcomes at 30 days were observed with both
devices in our registry, reflecting current TAVR
standards with next-generation THVs (3,27,28).
STUDY LIMITATIONS. Our study had a retrospective
observational design, with no core laboratory analysis
of procedural results and independent adjudication
of clinical events. We performed PS adjustment and
PS-matched comparison to overcome differences in
baseline characteristics and potential confounders;
however, a potential impact of unknown or unmea-
sured confounding factors on study outcomes cannot
be excluded. Furthermore, the different sample sizes
between the NEO and PRO groups in the overall
cohort and the relatively small numbers of patients
and events in the PS-matched groups may have
influenced study results.
CONCLUSIONS
In this multicenter registry, transfemoral TAVR with
the NEO and PRO bioprostheses was associated with
high device success, acceptable rates of moderate-to-
severe PAR, and good 30-day clinical outcomes. After
adjustment for potential confounders by means of PS-
matched analysis, short-term outcomes were similar
between the 2 next-generation self-expanding
devices.
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